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Summary. Parkinson’s disease (PD) is a slowly progressive neurodegenerative
disorder mainly characterized by degeneration of dopaminergic neurons in the
substantia nigra and the ventral tegmental area, in combination with a varying
loss of central noradrenergic (locus coeruleus), cholinergic (nucleus basalis of
Meynert) and serotonergic (dorsal raphe nuclei) integrity, leading to a multitude
of motor and non-motor behavioral disturbances.
Apart from the clinical motor hallmarks, in the early stages of disease,
subtle cognitive dysfunction might be seen comprising mainly executive dys-
function, with secondary visuospatial and mnemonic disturbances. In about
20–40% of patients, these problems may eventually proceed to dementia, which
constitutes an important risk factor for caregiver distress, decreased quality of
life and nursing home placement. Dementia in PD is typically characterized by
a progressive dysexecutive syndrome with attentional deficits and fluctuating
cognition, often accompanied by psychotic symptoms. It is thought to be the
result of a combination of both subcortical and cortical changes. PD-related
dopaminergic deficiency in the nucleus caudatus and mesocortical areas (due to
degeneration of projections from the substantia nigra and ventral tegmental
area) and cholinergic deficiency in the cortex (due to degeneration of ascending
projections from the nucleus basalis of Meynert), combined with additional
Alzheimer-pathology and cortical Lewy bodies, may greatly contribute to
dementia.
Current treatment of dementia in PD is based on compensation of the pro-
found cholinergic deficiency. Recent studies with the cholinesterase inhibitors
galantamine, donepezil and rivastigmine show promising results in improving
cognition and ameliorating psychotic symptoms, which must further be con-
firmed in randomized controlled trials.
Keywords: Parkinson’s disease, cognition, dementia.
Introduction
Parkinson’s disease is a slowly progressive neurodegenerative disease, in which
dopaminergic neurons in the substantia nigra and the ventral tegmental area
degenerate, leading to dopaminergic deficiency in the striatum and mesocorti-
colimbic areas. In addition to degeneration of the dopaminergic system, in PD
other ascending subcortical neurotransmitter systems are affected as well: the
cholinergic system (nucleus basalis of Meynert), the noradrenergic system
(locus coeruleus) and serotonergic system (dorsal raphe nuclei) (Jellinger,
1999). The cardinal motor symptoms are brady(hypo-)kinesia, tremor, rigidity
and postural instability. Non-motor symptoms mainly comprise autonomic dis-
turbances, depression, cognitive dysfunction=dementia and psychotic symp-
toms. As a rule, these symptoms are often more important in determining the
quality of life of patients and caregivers than the motor disturbances.
Dementia in PD constitutes not only an important factor for caregiver dis-
tress and nursing home placement (Aarsland, 2000, 1999), but is also associated
with increased mortality (independent of severity of motor symptoms) (Levy,
2000). As these symptoms are potentially treatable, identification is of major
clinical importance both for the patients and their caregivers and may enable
the Parkinson’s disease patient to maintain living at home for a longer period.
Additionally, postponement of nursing home placement can lead to substantial
reductions in healthcare costs.
Cognitive deficits in non-demented PD patients
Cognitive impairment is often associated with PD, although deficits may be
relatively subtle and not clinically apparent, or not overtly affect daily function-
ing. However, when compared to controls, subtle to prominent cognitive im-
pairment is almost always found in PD patients. A wide variety of cognitive
deficits has been described in non-demented PD patients, the most prominent of
which is a deficit in executive function.
Executive function is a broad term used to describe a range of cognitive
functions involved in the realisations of goal-directed, adaptive behaviour in
response to new, challenging environmental situations, including attention,
inhibition, task management, planning, monitoring and coding (Smith, 1999).
A dysexecutive syndrome, resembling cognitive deficits found in frontal lobe
patients (Rowe, 2002; Rogers, 1998a), is thought to be at the heart of cognitive
dysfunction and dementia in PD and is usually one of the earliest cognitive
symptoms found in PD (Dubois, 1997).
Besides executive dysfunction, there is considerable evidence of deficits in
visuospatial function in non-demented PD, even when tests contain few motor
components (Hovestadt, 1987; Boller, 1984; Bowen, 1972). Most authors,
however, believe visuospatial dysfunction to be the result of the high cognitive
demand that is usually required by such tasks. Indeed, with the possible excep-
tion of judgment of line orientation, it would appear that visuospatial dysfunc-
tion in PD can be readily explained by the demand of visuospatial tasks on
executive functions such as planning and (shifting of) attention (Bondi, 1993;
Raskin, 1992; Ogden, 1990; Ransmayr, 1987; Brown, 1986).
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Mnemonic dysfunction has also frequently been reported in PD. The most
consistent findings in patients with PD are deficits of working memory (Owen,
1993; Cooper, 1993, 1992; Bradley, 1989; Wilson, 1980) and explicit memory
(Buytenhuijs, 1994; Taylor, 1990, 1986). Working memory can be defined as
the ability to hold internal representations in short-term memory and to
manipulate this mnemonic information on line to enable adaptive behav-
iour to be based on these representations rather than on immediate stimuli
(Goldman-Rakic, 1987). Most studies find preserved short-term memory in
non-demented PD (Owen, 1997). The executive processes that operate on
the contents of this memory, however, are often impaired (Pillon, 1998).
Therefore, most deficits in working memory can probably also be explained
in terms of executive dysfunction. Defective explicit memory in PD can large-
ly be remedied by semantic cueing or probing (Scheltens, 1999; Pillon, 1993).
This suggests that although new information is stored, it is not readily
accessed, pointing to defective usage of stored information. In conclusion,
quite analogous to visuospatial function, mnemonic function would for the
most part be secondarily impaired, due to the reliance of its manifestation
on executive functionality.
Several studies have also shown bradyphrenia in PD (Cooper, 1994;
Mayeux, 1987), although this is still a matter of much controversy in the lit-
erature. It has been suggested that the finding of reduced cognitive speed may
very well have been caused by the inclusion of patients with mild dementia or
depression (Smith, 1998). For an excellent and comprehensive review of the
literature on cognitive deficits in PD, one is advised to read the chapter by
Pillon and co-workers in the recent Handbook of Neuropsychology (Pillon,
2001).
Dementia in PD
The aforementioned cognitive deficits may eventually proceed to dementia in a
number of patients. Prevalence and incidence vary considerably among studies,
possibly due to differences in patient population, study design and criteria for
diagnosing PD and dementia. In cross-sectional studies, prevalence of dementia
in PD ranges from 10% to over 40% (Aarsland, 1996; Mayeux, 1988, 1992).
Features associated with prevalence of dementia include age (Aarsland, 1996;
Mayeux, 1988), age at onset of PD (Aarsland, 1996; Mayeux, 1988, 1992),
disease severity (Mayeux, 1988), disease duration (Aarsland, 1996), depression
(Aarsland, 1996) and presence of atypical parkinsonian symptoms (Aarsland,
1996). The association with older age is of particular strength.
Prospective studies have reported a cumulative incidence of 19 to 53% (the
follow up period varied in these studies) (Read, 2001; Levy, 2000; Hughes,
2000; Marder, 1995). Recently, in a prospective study with 8 years follow-
up, 78.2% of patients eventually developed dementia (Aarsland, 2003a). Inci-
dence rates vary from 31.4 to 122.5 cases per 1000 person years (Aarsland,
1996, 2003a; Read, 2001; Hughes, 2000; Mahieux, 1998; Mayeux, 1990) and
the risk for developing dementia in PD-patients is up to six times higher com-
pared to age-matched control subjects (Aarsland, 2001).
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In these studies, factors associated with the risk of dementia were found to
be age (Levy, 2002; Aarsland, 2001; Read, 2001; Stern, 1993), age at onset of
PD (Mahieux, 1998), disease severity (Aarsland, 2001; Hughes, 2000; Marder,
1995; Elizan, 1986), age at entry in the study (Read, 2001; Hughes, 2000),
confusional state (Stern, 1993; Elizan, 1986), early hallucinations and the
mixed tremor=akinetic form of PD (Aarsland, 2003a).
The neuropsychological profile of PD-related dementia is characterized by a
progressive dysexecutive syndrome, as described earlier. Essentially, the same
types of deficits are found in non-demented patients (Girotti, 1988), but are
more severe in demented patients. From this perspective, it is not surprising
that several recent studies have pointed to the predictive value of prodromal
impairment of verbal memory (immediate and delayed recall) and especially
executive function (Woods, 2003; Levy, 2002; Jacobs, 1995).
Memory deficits are present, but are less severe compared to AD (Aarsland,
2003c). Moreover, the quality of memory impairment differs from that seen in
AD. In both conditions it is characterized by a deficit in free recall, but in PDD, as
mentioned before, this can often be corrected by semantic cueing (Scheltens,
1999). Therefore, in PDD the problem seems to be of retrieval, and not of encod-
ing. Indeed, recognition memory is often well preserved in demented PD-patients.
Unlike in AD, instrumental disorders such as aphasia, apraxia or agnosia are
not very common in PDD (Dubois, 1997; Huber, 1989).
Psychotic symptoms however, are especially common in PDD. Hallucina-
tions (sensory percepts in the absence of an external stimulus (American Psy-
chiatric Association, 1994)), mainly visual, are the most frequent symptom.
These are mostly non-threatening and often consist of vivid, colourful and
sometimes fragmented figures of beloved (deceased) familiar persons and=or
animals, which are described in detail (Poewe, 2003). Insight is retained in the
majority of occasions, but with reality testing deteriorating, the hallucinations
may change and become more frightening, possibly inducing anxiety and panic
attacks (Wolters, 2001). Loss of insight is particularly seen in demented patients
(Fenelon, 2000). Delusions (false beliefs based on incorrect inference about
external reality (American Psychiatric Association, 1994)) are less common
than hallucinations and mainly of the paranoid type, dealing with persecution,
spousal infidelity or jealousy (Bosboom, 2004).
Attentional deficits and fluctuating cognition are also very common in PDD.
These features, together with parkinsonism and the above mentioned visual
hallucinations, are the main characteristics of dementia with Lewy bodies
(DLB), possibly accounting for 15–20% of the dementias (McKeith, 1996).
Indeed, PDD and DLB share many clinical (Ballard, 2002; Connor, 1998;
Dubois, 1997) and pathological (Harding, 2001) features and are often difficult
to distinguish other than by the temporary onset of dementia and psychosis in
relation to parkinsonism (Richard, 2002). Therefore, Parkinson’s disease and
dementia with Lewy bodies are often considered to be part of the same disease
spectrum (Burn, 2003a; Ballard, 2000; McKeith, 2000b), although this matter is
still under considerable debate (Litvan, 1998). It is suggested that similar patho-
logical mechanisms may underlie the clinical symptoms, including dementia
and psychotic symptoms.
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Pathophysiology of cognitive deficits and dementia in PD
Based on his work in primates, Alexander described five parallel, segregated
circuits interconnecting well-defined subregions of the basal ganglia to partic-
ular cortical fields via the thalamus (Alexander, 1986). Disruptions at either
basal ganglia or cortical points in such a circuit have been shown to produce
similar behavioural effects (Cummings, 1993). In one of the five circuits, the
so-called dorsolateral prefrontal loop which is thought to be involved in execu-
tive behaviour, the dorsolateral part of the prefrontal cortex projects to the
caudate nucleus. Hence projections lead trough pallidum and thalamus back
to the prefrontal cortex. It may therefore well be that degeneration of the dopa-
minergic nigrostriatal pathway affects executive function by causing a disrup-
tion at the level of the caudate nucleus, a notion supported by findings from
imaging studies (Lewis, 2004; Owen, 1998). This notion is further underlined
by the fact that dopamine depletion in PD is greatest in the caudate’s most
rostral portion, exactly the part that is most heavily interconnected to the dor-
solateral region of the prefrontal cortex.
Alternatively, cognitive dysfunction in non-demented PD could be caused
by dopamine depletion in the frontal cortex itself, resulting from degeneration
of the mesocortical dopaminergic system mainly projecting from the ventral
tegmental area. In any case, the exact contribution of dopaminergic deficiency
to cognitive defects in Parkinson’s disease remains controversial, largely be-
cause the cognitive effects of dopaminomimetics appear heterogeneous. While
some studies point to a positive effect on executive function (Lange, 1992,
1995), (working)memory and attention (Bowen, 1975), others actually find
deleterious effects, especially in the executive domain (Gotham, 1988) or
show no effects at all. A recent longitudinal study showed the beneficial ef-
fect of dopaminergic medication to be particularly prominent in the very
early stages of disease (Kulisevsky, 2000b) (for a review of the pertinent
literature, read (Kulisevsky et al., 2000a)). Also, cognitive function in PD
seems to correlate with motor symptoms that show little response to dopa-
minergic treatment (axial symptoms and gait disturbances), but not with
levodopa-responsive symptoms (akinesia and rigidity) (Burn, 2003b; Levy,
2000; Pillon, 1989).
In conclusion, it would appear that dopaminergic medication improves or
impairs cognitive performance depending on both the nature of the task and
the basal level of DA function in underlying nigrostriatal and mesocortical
circuitry.
The exact pathophysiology of dementia in PD is uncertain. A number of
neuropathological and neurochemical changes in PD are thought to be involved.
The aforementioned deterioration of the dopaminergic system is likely to
contribute to the progression of cognitive deficits into more overt dementia.
This is supported by the association between dementia and the loss of dopami-
nergic neurons in the medial part of the substantia nigra (Paulus, 1991; Rinne,
1989), projecting to the nucleus caudatus and mesocortical and mesolimbic
areas, and in the ventral tegmental area, with ascending dopaminergic projec-
tions to mesocortical and mesolimbic areas (Oades, 1987; Thierry, 1978).
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Still, dopaminergic deficiency by itself is not considered sufficient for the
development of dementia. Non-dopaminergic systems are likely to be involved
as well. As already mentioned, several neuromodulatory systems are affected to
varying degree in PD, mainly the serotonergic, noradrenergic and cholinergic
systems (Jellinger, 1999).
Neuronal loss in locus coeruleus (LC) and noradrenergic deficiency in
the cortex were reported to be associated with dementia in PD (Cash, 1987).
However, in other studies, this relationship could not be found (Paulus, 1991;
Chan-Palay, 1989). Loss of serotonergic neurons in the dorsal raphe nucleus
(DRN) has mainly been associated with depression, but demented and non-
demented patients did not differ on neuronal counts in this area (Paulus,
1991; Scatton, 1983).
Furthermore, Perry et al. (1991) could not establish a correlation between
dementia in PD and diminished monoaminergic activity. Instead, they reported
an association between cholinergic deficiency and dementia. Indeed, not only in
Alzheimer’s disease (Francis, 1999; Davies, 1976), but especially in PDD and
DLB, a cholinergic deficit has been implicated in the pathophysiology of cog-
nitive impairment. In these patients, a definite and more pronounced depletion
of cholinergic neurons is found in the nucleus basalis of Meynert compared to
AD-patients and non-demented patients (Perry, 1985; Whitehouse, 1983),
together with diminished cholinergic activity in the cortex (Ballard, 2002;
Mattila, 2001; Tiraboschi, 2000; Perry, 1991). This nucleus in the basal fore-
brain, consisting for 90% of cholinergic neurons, provides major cholinergic
projections to the amygdale and neocortex (Perry, 1985; Whitehouse, 1983;
Mesulam, 1983a, b). The cholinergic deficit, possibly superposed on a normal
age-related deterioration of the cholinergic system (Perry, 1992), is strongly
correlated with cognitive impairment in both conditions (Mattila, 2001; Kuhl,
1996; Perry, 1985) and therefore, is likely to constitute an important mechanism
in the development of dementia.
This is further supported by the propensity of anticholinergic agents to elicit
cognitive dysfunction in PD-patients (Bedard, 1999; de Smet, 1982) and the
clinical beneficial results of cholinesterase inhibitors in disorders with asso-
ciated dementia (see later).
Beside these subcortical neuropathological changes in PDD, important cor-
tical changes have been implicated in the etiology of dementia in PD. AD-
pathology, especially AD-neurites, are more abundant in demented patients
compared to non-demented PD-patients, correlating with the severity of PDD
in a number of studies (Jellinger, 2002; de Vos, 1995), though other authors
point to the importance of cortical LB’s as a neuropathological substrate for
dementia in PD (Apaydin, 2002; Harding, 2001; Hurtig, 2000; Mattila, 2000),
independent of AD-pathology (Hurtig, 2000; Mattila, 1998, 2000). This, how-
ever, is opposed by authors reporting comparable cortical LB distribution
in demented and non-demented PD-patients (Richard, 2002; SantaCruz, 1999;
de Vos, 1995). Thus, this matter is still under considerable debate.
Overall, dementia in PD is thought to be the result of a combination of
several subcortical and cortical pathological changes. Subcortical mechanisms
include both dopaminergic deficiency in the nucleus caudatus and mesocortical
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areas, causing executive dysfunction, and cortical cholinergic deficiency, mainly
due to degeneration of the nucleus basalis of Meynert. The latter may further
deteriorate the patient’s executive functions by inducing attentional deficits
(possibly together with noradrenergic deficiency). This effect might be in-
creased by ageing. Additional AD-like changes and the presence of Lewy bodies
in the cortex are likely to further compromise cognitive functions, with devel-
opment of dementia as soon as a certain threshold is reached (Wolters, 1998).
Treatment of dementia in PD
Current pharmacological intervention in dementia is symptomatic and is based
on compensation for the profound loss of cholinergic activity in the cortex. In
AD, modest beneficial results have been reported with the cholinesterase inhib-
itors galantamine, rivastigmine and donepezil (Gabelli, 2003; Tariot, 2000;
Cummings, 1998; Rogers, 1998b). These compounds might even prove to be
more effective in PDD (and DLB) for several reasons. First, as mentioned
above, the deterioration of ascending cholinergic projections from the nucleus
basalis of Meynert is probably more pronounced in PDD and DLB compared to
AD (Perry, 1985; Whitehouse, 1983). Second, the cortex is thought to be rela-
tively spared in PDD (Perry, 1993).
An early study with tacrine in PD reported a definite amelioration of psy-
chotic behaviour (Hutchinson, 1996), but this compound has been withdrawn
from the market because of hepatotoxicity.
Galantamine and donepezil are cholinesterase inhibitors that stimulate the
nicotinic receptor (Samochocki, 2000). In open label studies with these com-
pounds, cognition as well as hallucinations improved in PD-patients with
dementia without significant worsening of extrapyramidal features (Aarsland,
2003b; Bergman, 2002; Fabbrini, 2002; Werber, 2001).
Open label studies with rivastigmine, a dual acetyl and butyryl cholinester-
ase inhibitor have yielded similar results in PDD as well as DLB (Giladi, 2003;
Bullock, 2002; Grace, 2001; Reading, 2001; McKeith, 2000a, c). In these stud-
ies, extrapyramidal features did not worsen significantly and even tended to
improve in one (Reading, 2001) and worsened after withdrawal of rivastigmine
in another (McKeith, 2000c). Given the possible parkinsonism inducing effects
of cholinergic drugs, the improvement as seen in the motor scores of the
Parkinson’s disease patients treated with cholinesterase inhibitors is unex-
pected. In our own (unpublished) experience rivastigmine only tends to increase
tremor in demented PD-patients.
The only randomized controlled trial with cholinesterase inhibitors in PDD
so far, has been conducted with donepezil. The same beneficial results as in the
previous open label studies have been reported, though the number of patients
was small (Aarsland, 2002). A large, randomized, placebo controlled trial with
rivastigmine in PDD, is currently being conducted.
The most frequent side effects reported with the use of cholinesterase inhib-
itors are nausea, vomiting and anorexia, sometimes causing problems with drug
titration. Therefore, the drugs should be started at low dose with a gradual
increase to the maximum tolerated dose.
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